Saltar al contenido
Merck

V3003

Sigma-Aldrich

Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-2 (KDR) antibody produced in mouse

clone 260.4, KDR-2, ascites fluid

Sinónimos:

Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-2 antibody produced in mouse, Anti-KDR, Anti-VEGFR-2

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

UNSPSC Code:
51111800
NACRES:
NA.41

biological source

mouse

Quality Level

conjugate

unconjugated

antibody form

ascites fluid

antibody product type

primary antibodies

clone

260.4, KDR-2, monoclonal

contains

15 mM sodium azide

species reactivity

human

technique(s)

immunohistochemistry (frozen sections): suitable
indirect ELISA: suitable
western blot: 1:500 using insect cell culture supernatant expressing human extracellular recombinant VEGFR or VEGF Receptor-2 (KDR, FLK-1)/FC Chimera human, recombinant

isotype

IgG1

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... KDR(3791)

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-2 (mouse IgG1 isotype) is derived from the KDR-2 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from an immunized mouse. Vascular endothelial growth factor receptor 2 (VEGFR2) is a type V receptor tyrosine kinase, also known as kinase insert domain receptor (KDR) or fetal liver kinase 1 (Flk-1). It a glycosylated protein with an immunoglobulin (Ig)-like domains, a transmembrane domain and a tyrosine kinase domain. The KDR gene is mapped to human chromosome 4q12 and is widely expressed in all vessel-derived endothelial cells and hematopoietic stem cells.

Specificity

Reacts specifically with human VEGF receptor-2. This clone has also been termed 260.4. It does not recognize Flt1 (VEGFR-1), Flt4 (VEGFR-3), or platelet-derived growth factor receptor (PDGF-R).

Immunogen

purified recombinant human extracellular VEGF receptor-2 (KDR).

Application

Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-2 (KDR) antibody produced in mouse has been used in:
  • immunofluorescence
  • immunohistochemistry
  • immunoblotting
  • enzyme-linked immunosorbent assay(ELISA)

Biochem/physiol Actions

Vascular Endothelial Growth Factor Receptor-2 (VEGF R2) have high affinity for vascular endothelial growth factor-A (VEGF-A), hence facilitates most of the endothelial growth and survival signals from VEGF-A. It also plays a pivotal role in vascular development, vascular permeability, embryonic hematopoiesis and regulation of angiogenesis.
Vascular endothelial growth factor receptor 2 (VEGFR2) or kinase insert domain receptor (KDR) is a VEGF receptor, which stimulates its mitogenic activity. It is crucial for vascular endothelial cell development. VEGFR2 expression is elevated in invasive breast cancer, hemangiomas and angiosarcomas. KDR expressing cells show striking changes in cell morphology, actin reorganization and membrane ruffling, chemotaxis, and mitogenicity in response to VEGF. Antibodies that react specifically with the VEGF receptor are useful for the study of the specific differential tissue expression and intracellular localization of the receptor in normal and neoplastic tissue.

Target description

The KDR receptor (VEGFRa), defining marker of hematopoietic stem cells (HSCs), distinguishes pluripotent HSCs from lineage-committed progenitor HSCs.

Physical form

The product is provided as ascites fluid with 15 mM sodium azide as a preservative.

Storage and Stability

For continuous use, store at 2-8 °C for up to one month. For extended storage freeze in working aliquots. Repeated freezing and thawing, or storage in "frost-free" freezers,is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

¿No encuentra el producto adecuado?  

Pruebe nuestro Herramienta de selección de productos.

Storage Class

10 - Combustible liquids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Masabumi Shibuya
Cancer science, 94(9), 751-756 (2003-09-12)
Vascular endothelial growth factor receptor-2 (VEGFR-2/KDR/Flk-1) is a high-affinity receptor for vascular endothelial growth factor-A (VEGF-A), and mediates most of the endothelial growth and survival signals from VEGF-A. VEGFR-2 has a typical tyrosine kinase receptor structure with seven immunoglobulin (Ig)-like
J M Ou et al.
European journal of histochemistry : EJH, 58(1), 2263-2263 (2014-04-08)
Angiogenesis is a process of development and growth of new capillary blood vessels from pre-existing vessels. Angiogenic growth factors play important roles in the development and maintenance of some malignancies, of which vascular endothelial growth factor (VEGF)/VEGFR2 interactions are involved
S Ogawa et al.
The Journal of biological chemistry, 273(47), 31273-31282 (1998-11-13)
Vascular endothelial growth factor (VEGF) mediates endothelial cell proliferation, angiogenesis, and vascular permeability via the endothelial cell receptors, KDR/Flk-1 and Flt-1. Recently, a gene encoding a polypeptide with about 25% amino acid identity to mammalian VEGF was identified in the
Irawan Satriotomo et al.
Experimental neurology, 237(1), 103-115 (2012-06-19)
Acute intermittent hypoxia (AIH) initiates plasticity in respiratory motor control, including phrenic long term facilitation (pLTF). Since pLTF is enhanced by preconditioning with repetitive exposure to AIH (rAIH), we hypothesized that a rAIH protocol consisting of 3 AIH exposures per
I Satriotomo et al.
Neuroscience, 322, 479-488 (2016-03-06)
Repetitive acute intermittent hypoxia (rAIH) increases growth/trophic factor expression in respiratory motor neurons, thereby eliciting spinal respiratory motor plasticity and/or neuroprotection. Here we demonstrate that rAIH effects are not unique to respiratory motor neurons, but are also expressed in non-respiratory

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico